Genesis Biopharma appoints new ceo and cfo

Anthony Cataldo and Michael Handelman also join board of directors

Genesis Biopharma, a US biotechnology company developing targeted cancer therapies, has named Anthony Cataldo as president and chief executive. He succeeds Robert Brooke, who is now a strategic advisor to the Manhattan Beach, California-based company.

In addition Genesis Biopharma has appointed Michael Handelman as chief financial officer, treasurer and secretary, succeeding Richard McKilligan.

Cataldo and Handelman have joined the company's Board, while Brooke, McKilligan and Mark Ahn have resigned as members.

‘I'm looking forward to working with the Genesis Biopharma board to further the progress of our important cancer technology, and to develop new strategic opportunities to build shareholder value,’ said Cataldo.

‘Genesis Biopharma's targeted anti-CD55 monoclonal antibody technology has widespread clinical utility, as it neutralises a key cancer defence mechanism that is over-expressed in more than 80% of tumours. It could provide a safe alternative to toxic chemotherapy regimens, and has the potential to expand and improve the clinical utility of already approved antibody therapies as well as some novel agents in development.’

Cataldo was formerly chairman, chief executive and a director of Oxis International. Prior to this he was non-executive co-chairman of the Board of MultiCell Technologies.

Handelman was chief financial officer of Oxis International. Prior to this he was cfo and coo of TechnoConcepts.

You may also like

Manufacturing

Nulogy launches Supplier Compliance Management to build stronger, more resilient supplier networks

Nulogy, a leading provider of manufacturing operations software, announced the launch of Nulogy Supplier Compliance Management, a solution designed to centralise and automate supplier compliance for procurement, supply chain, and quality assurance teams in manufacturing, food & beverage, pharmaceuticals, and other highly regulated industries
Regulatory

TurboFil debuts latest generation of through-the-tip benchtop syringe filler

TipFil Plus provides precise, aseptic-ready filling and capping for lab and pharmacy applications
Manufacturing

Concentrating recombinant proteins for drug discovery using centrifugal evaporation

Exploring purification, concentration and sample protection in recombinant protein workflows
Research & Development

COVID-19 immunity lowers the risk of a new pandemic

Researchers at the MRC-University of Glasgow Centre for Virus Research have demonstrated that the likelihood of the emergence of a new SARS-type virus pandemic has been significantly reduced by population-wide immunity to SARS-CoV-2
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Cytiva enters research partnership with SRTIGET for next-gen genomic medicine

The pair aim to expand the role of lipid nanoparticle technology into gene therapy delivery, including applications in cancer and inherited blood diseases, CNS delivery for neurological disorders where current methods fail and in vivo stem cell modification that could eliminate toxic conditioning regimens
Research & Development

Shimadzu’s Design Craftech

Fusing traditional Kyoto craft techniques with industrial production
Research & Development

Just – Evotec Biologics wins BARDA contract to optimise antibody biomanufacturing against Ebola and Sudan virus

Just – Evotec Biologics has been selected by BARDA to develop scalable, high-yield manufacturing processes for a monoclonal antibody cocktail targeting filovirus diseases under a multi-year programme valued at up to $10m
Subscribe now